P/E ratio for Inotiv (NOTV)
P/E ratio as of May 2024 (TTM): -0.3135
According to Inotiv's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.313489. At the end of 2022 the company had a P/E ratio of -0.3703.
P/E ratio history for Inotiv from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.3703 | -97.17% |
| 2021 | -13.1 | -66.01% |
| 2020 | -38.4 | 55.3% |
| 2019 | -24.8 | -41.54% |
| 2018 | -42.3 | -295.52% |
| 2017 | 21.7 | -1022.04% |
| 2016 | -2.35 | -107.72% |
| 2015 | 30.4 | -141.83% |
| 2014 | -72.7 | -46.37% |
| 2013 | -136 | 5678.68% |
| 2012 | -2.34 | 74.46% |
| 2011 | -1.34 | -89.87% |
| 2010 | -13.3 | 1290.08% |
| 2009 | -0.9541 | -56.82% |
| 2008 | -2.21 | -102.04% |
| 2007 | 108 | -671.43% |
| 2006 | -19.0 | -15.63% |
| 2005 | -22.5 | -131.47% |
| 2004 | 71.4 | -252.38% |
| 2003 | -46.9 | -494.92% |
| 2002 | 11.9 | -32.27% |
| 2001 | 17.5 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Nymox Pharmaceutical NYMX | -3.33 | 963.30% | Bahamas |
 NRC Health
NRC | 29.4 | -9,474.05% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.